Please login to the form below

Not currently logged in
Email:
Password:

Lemtrada

This page shows the latest Lemtrada news and features for those working in and with pharma, biotech and healthcare.

Sanofi highlights MS drug data as it swings to a loss in Q4

Sanofi highlights MS drug data as it swings to a loss in Q4

For 2019 as a whole it topped 2.1bn in sales. Sanofi already has an established MS franchise with oral therapy Aubagio (teriflunomide) and Lemtrada (alemtuzumab), but that declined 3% to

Latest news

  • Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations Novartis’ Mayzent and Roche’s Polivy lead CHMP recommendations

    Safety reviews of Lemtrada and Xeljanz. In addition to approving a number of new drugs, the CHMP also restricted the use of two medicines. ... This includes Sanofi Genzyme’s multiple sclerosis medicine  Lemtrada(alemtuzumab), which now has restricted

  • Sanofi settles Lemtrada dispute with Genzyme investors for $315m Sanofi settles Lemtrada dispute with Genzyme investors for $315m

    It also pledged to take 'diligent effort' to get Lemtrada through development and onto the market quickly. ... It also claimed the company didn’t make the effort required for Lemtrada to reach its sales targets.

  • NICE backtracks on Biogen's multiple sclerosis drug Zinbryta NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

    the disease if they have failed to respond to first-line treatment with Sanofi's Lemtrada (alemtuzumab) or have rapidly evolving severe MS.

  • Celebrating excellence Celebrating excellence

    The London-based agency picked up The Cello Health Award for Launch Excellence for work on behalf of Genzyme and its multiple sclerosis treatment Lemtrada. ... Lucid also picked up the Cello Health Award for Launch Excellence Award for supporting Genzyme

  • Lucid behavioural change programmes recognised at PMEA Lucid behavioural change programmes recognised at PMEA

    The London-based agency picked The Cello Health Award for Launch Excellence for work on behalf of Genzyme and its multiple sclerosis treatment Lemtrada. ... Lucid also picked up the Cello Health Award for Launch Excellence Award for supporting Genzyme

More from news
Approximately 9 fully matching, plus 20 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Covid-19: how is it affecting prescribing patterns?

    Between May 2019 and May 2020, there was a reduction in several key treatments: Lemtrada, Tysabri and Gilenya. ... Lemtrada is a monoclonal antibody (MAB) given by infusion. Tysabri, or natalizumab, is also an infusion injection.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....